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Protozoa and helminths are the two main groups that cause parasitic diseases with a broad
spectrum of clinical symptoms. Protozoa are unicellular organisms like the malaria para-
site Plasmodium, which is responsible for the majority of deaths associated with parasitic
infections. Helminths are alternative parasites that can produce debilitating diseases in
hosts, some of which result in chronic infections. The discovery of effective therapeutic
drugs is the key to improving health in regions of poverty and poor sanitation where these
parasites usually occur. It is very encouraging that the 2015 Nobel Prize in Physiology or
Medicine was awarded to Youyou Tu as well as William C. Campbell and Satoshi ~Omura for
their considerable contributions in discovering artemisinin and avermectin, respectively.
Both drugs revolutionized therapies for filariasis and malaria, significantly reducing by
large percentages their morbidity and mortality.Malaria is one ofmost important parasitic diseases, remaining
a major health problem in most tropical developing countries
in Africa, Asia, and Latin America. The Plasmodium protozoans
P. vivax, P. ovale, P. malariae, P. falciparum, and/or P. knowlesi are
the etiological agents of malaria in humans, and all are
transmitted by Anopheles mosquitoes in nature [1]. Approxi-
mately 3.4 billion people worldwide are exposed annually and
1.2 billion of them are at high risk. Of these, 198 million ma-
laria cases with clinical symptoms were reported in 2013,
causing at least 650,000 deaths every year [2]. In addition to
being a health threat, endemic malaria is an economic and
social burden, particularly in low income countries [3].
Nematodes or roundworms like whipworm, pinworm,
hookworms, and filariae are also important human parasitesblic Health and Parasitolo
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s/by-nc-nd/4.0/).that currently or formerly occurred widely in tropical regions
of the world. A number of nematodes are intestine-dwelling;
however, filariae mostly live in other tissues, such as lym-
phatics and skin. Onchocerca volvulus, which causes oncho-
cerciasis, is one important species naturally transmitted by
black flies (Simulium spp.). Adults ofO. volvulus usually develop
a nodular form under the skin, frequently resulting in dis-
figuring skin conditions, visual impairment, and even per-
manent blindness (river blindness). Onchocerciasis is
geographically distributed in sub-Saharan Africa and parts of
Latin America. Meanwhile, Wuchereria bancrofti and Brugia
malayi/Brugia timori are the species transmitted bymosquitoes
and cause clinical symptoms similar to those of elephantiasis
(lymphatic filariasis); i.e., impaired lymphatic drainage,gy, College of Medicine, Chang Gung University, 259, Wenhua 1st
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Fig. 1 e (A) Artemisinin identified from Artemisia annua contains an endoperoxide bridge reacts with the iron atoms, leading to
disruption on the hemoglobin catabolism and heme detoxification systems in the food vacuole of Plasmodium species by
forming free radicals. Malaria parasites developing inside the erythrocyte are consequently damaged which treated with
artemisinin. (B) Streptomyces avermectinius e originated avermectin possesses activity against nematodes including those cause
river blindness and lymphatic filariasis by binding to glutamate-gated chloride channels in treated parasites, causing increased
chloride ion influx and hyperpolarization of the parasite nerves. It, in turn, interferes with the transmission of nerve signals,
leading to paralysis and death of the parasite in consequence.
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occur in the tropics and it has been identified by the World
Health Organization as the second leading cause of perma-
nent or long-term disability [6].
Treatment for patients is essential in order to prevent
morbidity and mortality, and conventional drugs have been
developed against both important parasites. Quinine/chloro-
quine was identified as effective against malaria decades or
even centuries ago. In contrast, diethylcarbamazine (N, N-
diethyl-4-methyl-1-piperazine carboxamide; DEC or Hetra-
zan) was developed and has been used to treat filariasis since
the last mid-century. Unfortunately, their efficacies have
largely decreased due to induced resistance caused by the
prevalent use of these drugs over time. Discoveries of arte-
misinin and avermectin have recently opened a new era of
chemotherapy for these two important parasitic diseases, not
only relieving a number of diseases but also savingmany lives
from infections.Discovery of artemisinin
The malaria parasite was not identified until the military
doctor Alphonse Laveran described his finding in “New para-
site found in the blood of several patients suffering from
marsh fever” in 1802. Its natural cycle via transmission by
Anopheles mosquitoes between humans was subsequently
demonstrated by Ronald Ross a few years later [7]. Humans
and female mosquitoes both provide adequate environments
for the development of malaria parasites in their complex life
cycle [8]. In humans, the parasite forms male (micro-) and
female (macro-) gametocytes as the final developmental
stage, which are ingested by mosquitoes along with a blood
meal. The opposite gametocyte sexes subsequently mate inthe lumen of the midgut where infective sporozoites form
within the resultant oocysts. They thenmigrate to the salivary
glands, from which they can be passed along with saliva to
another human when infected female mosquitoes bite again
[9]. After injection into humans via mosquito bites, sporozo-
ites rapidly multiply in the liver to form merozoites, which
then invade red blood cells in the bloodstream. Infected red
blood cells usually burst and release merozoites, which
cyclically enter and infect other red blood cells. This feature
results in typical clinical symptoms such as chills and fever, as
well as anemia in most cases. Complications like cerebral
malaria, acute renal failure, black water fever, hypotension,
shock, and even death also occur in many cases of P. falcipa-
rum infection [10].
Quinine was identified from the bark of Cinchona (Family:
Rubiaceae) as early as 1820, while its first derivate compound,
chloroquine, was first synthesized in 1934 and has since been
used as a therapeutic for malaria [11]. Unfortunately, resis-
tance to chloroquine appeared in most of the areas harboring
malaria by the late 1960s while the incidence of the disease
continued to rise [12]. This makes it urgent to develop new
approaches to replace chloroquine in malaria treatment and
control. Artemisinin was first identified in 1972 by Youyou Tu
and her team in the Academy of Traditional Chinese Medi-
cine, China (ScienceNet.cn; http://tinyurl.com/gkw7mjh).
After graduating from Peking University Medical School/Bei-
jing Medical College with a major in Pharmaceutical Sciences,
Youyou Tu started working on traditional herbal medicine in
1955. During the Cultural Revolution period in China, Youyou
Tu was appointed the director of Project 523 in 1969, which
strove to develop novel therapeutic drugs to heal chloroquine-
resistant malaria. In a large-scale screening of herbal medi-
cines, Artemisia spp. (Family: Asteraceae), or sweet worm-
wood, was selected from more than 640 traditional herb
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(Science Net; http://tinyurl.com/gkw7mjh).
Artemisia has been used as an ancient Chinese medicine to
relieve fever for more than 2000 years [13]. The active ingre-
dient extracted from Artemisia annua but not Artemisia apiacea
(both species of plants grow commonly in China), later called
artemisinin, was demonstrated to be effective against Plas-
modium infections. In order to overcome inconsistent experi-
mental results, Youyou Tu revisited a Chinese ancient
manuscript called “The handbook of prescriptions for emer-
gency treatments (肘後備急方 in Chinese)”written in 340 BC by
Ge Hong (葛洪 in Chinese). Upon inspiration from that book,
she changed the protocol for component extraction by using
ether, which has a low boiling point (35 C), in place of water
and ethanol [14]. Youyou Tu was ultimately able to obtain
artemisinin from the new extraction process, from which an
ingredient highly effective against the development ofmalaria
parasites was obtained in 1972 [15]. Later, water-soluble de-
rivative compounds such as artesunate and OZ 277 were
synthesized for use in injections [16,17].
The acidic food vacuole is one of the essential organelles in
the intra-erythrocyte stages of malaria parasites [18]. This
vacuole has a role in the digestion of host hemoglobin, the
iron-containing oxygen-transport metalloprotein in the red
blood cells of all vertebrates [19]. Malaria parasites developing
in erythrocytes generally transport a large quantity of eryth-
rocytic cytoplasm to the food vacuole, within which hemo-
globin is degraded [20]. During hemoglobin catabolism,
potentially toxic heme moieties are polymerized to become
hemozoin, or malaria pigment [21], which also provides iron
to the parasite [20]. Structurally, artemisinin contains two
oxygen atoms linked together and known as an endoperoxide
bridge, which reacts with iron atoms [22] and leads to the
disruption of hemoglobin catabolism and heme detoxification
systems in Plasmodium species by forming free radicals [23].
Ultrastructural studies have revealed that artemisinin
frequently causes disruption of the food vacuole membrane
and extensive loss of organelle structures at longer incubation
times, suggesting that the food vacuole is an important initial
site of endoperoxide antimalarial activity [24]. As a result,
artemisinin becomes toxic to malaria parasites when it reacts
with the high iron content of the parasites to generate free
radicals [Fig. 1A], which damage the parasite [25]. Further-
more, the regular function of the electron transport chain
within the mitochondria of the malaria parasite may also be
damaged [26,27]. Perhaps it is caused by the disruption of the
mitochondrial membrane in response to artemisinin used
againstmalaria parasites [24]. Sincemitochondria do not exist
in erythrocytes, artemisinin does not cause such damages to
the erythrocyte and thus could be specifically effective against
malaria parasites.Discovery of avermectins
A number of nematode parasites are accommodated in the
intestine. Such intestine-dwelling nematodes include Ascaris
lumbricoides, Trichuris trichiura, Enterobius vermicularis, and
Strongyloides stercoralis, which occur particularly commonly in
tropical regions [28]. Four chemotherapeutic anthelminticdrugs in two main groups have long been recommended by
WHO for treating these infections. Albendazole and meben-
dazole belong to the benzimidazoles group, while levamisole
and pyrantel are in the imidazothiazoles/tetrahydropyr-
imidines group [29]. These anthelmintics are basically safe
with few or no side effects in the treatment of nematode
parasites within the human intestine [29]. A large proportion
of infections of intestinal nematode parasites have evidently
been reduced after extensive mass treatment.
There are many nematodes that regularly live outside the
intestinewith different environments; e.g., filariae. As a result,
traditional anthelmintics that work by expelling intestinal
nematodes are useless in the treatment of filariae [30]. Filariae
are naturally transmitted by blood-feeding insects. Adult
parasites develop and mate in specific tissues and produce
microfilariae in the host. Among them, W. bancrofti and B.
malayi are the main species occurring in tropical and sub-
tropical countries [31]. Both reside in lymphatics and
frequently cause lymphatic filariasis with a variety of clinical
manifestations, including lymphedema of the limbs, and
genital diseases such as hydrocele, chylocele, and swelling of
the scrotum [32]. In the mosquito vector, the microfilariae
ingestedwith bloodmeals developmostly in thoracicmuscles,
migrate to the mosquito's mouthparts, and then infective
larvae (L3) enter a new host via blood-feeding [32]. O. volvulus
causes river blindness, the commonest infectious blindness in
the world, which occurs primarily in Africa and with limited
distribution in Latin America. This parasite is naturally
transmitted by black flies (Simulium spp.), whose larval stages
are spent in swift streams [33]. The L3 of O. volvulus are
deposited when infected black flies feed again, subsequently
developing into adult filariae at several locations on a person's
skin, generating nonspecific symptoms and severe pruritus,
acute and chronic dermatitis, vitiligo-like hypopigmentation,
and atrophy [34]. Migration ofmicrofilariae into eyes can cause
ocular disease that leads to blindness in severe cases [35].
Albendazole has ever been used as a drug to eliminate
lymphatic filariasis; unfortunately, it has little effect on
reducing microfilariae abundance in the host [36]. Diethyl-
carbamazine (DEC), discovered by Yellapragada Subbarow,
was subsequently used against filarial infections from the
early 1950s [37]. Pharmacologically, DEC is an inhibitor of
arachidonic acid metabolism in filarial microfilaria [38] that
facilitates the loss of the microfilarial sheath and results in
body damage [39]. Treated microfilariae but not adult worms
become more susceptible to attack by the innate immunity of
the host [38]. Adult worms remaining in tissues stay alive and
reproductive, persistently producingmicrofilariae thatmay be
picked upwhen the host is bitten again by black flies. Ingested
microfilariae then migrate within the host, possibly causing
clinical outcomes that include blindness in severe cases. In
addition, DEC administration frequently causes a wide spec-
trum of side effects such as fever, headache, dizziness,
nausea, and muscle or joint pain [40]. It may also worsen eye
disease caused by O. volvulus (CDC website, http://tinyurl.
com/zn7kbca). Such disadvantages remained until the time
Satoshi ~Omura, a Japanese microbiologist and a professor in
the School of Pharmaceutical Sciences, Kitasato University,
isolated avermectins from Streptomyces (a part of Actino-
bacteria) (Nobelprize.org: http://tinyurl.com/od8efal). As with
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finding of avermectin is astonishing and undoubtedly a
serendipity [41]. The journey of the discovery started in 1973
by a unique collaboration between international laboratories
or sectors affiliated to governments, non-governmental or-
ganizations, and industry.
A team was then formed to discover a drug effective
against helminth parasites to reduce their impacts on the
poverty-stricken. Within the program, Satoshi ~Omura pro-
posed research activities to search for novel antibiotic agents
from natural organisms [42]. Not long afterward, a new strain
of Streptomyces avermectinius, an actinomycete, was isolated
from soil samples and successfully cultured in the laboratory.
Streptomyces is a group of Gram-positive bacteria resembling
filamentous fungi in shape fromwhich a number of secondary
metabolites with the bioactivity of antibiotics and related
products have been obtained [43]. Among such cultures,
Satoshi ~Omura selected about 50 that were promising against
harmful microorganisms [41]. William C. Campbell, a profes-
sor at Drew University, Madison, NJ, USA, and an expert in
parasite biology, obtained Streptomyces cultures from Satoshi
~Omura and found that a component from one of the cultures
was remarkably efficient against parasites commonly seen in
domestic and farm animals in 1974 [42]. The component was
then purified and named Avermectin, and subsequently was
determined to be a series of macrocyclic lactone derivatives
[44]. Despites lacking significant antibacterial or antifungal
activity, in contrast, avermectin was shown to have activity
against helminths, especially nematodes, through a screening
system conducted at Merck Sharp & Dohme Research Labo-
ratories in Rahway, NJ [45]. It is particularly useful in treating
the adult stage of O. volvulus andW. bancrofti/B. malayi, which
are not responsive to DEC in most cases nowadays [46].
After chemically modifying avermectin, a more effective
compound called ivermectin (a dihydro derivate of avermec-
tin) was obtained and found effective in killing filariae in
humans [45]. Ivermectin has proven to be one of the most
successful therapeutic drugs for filariasis [47], usually by
causing the paralysis of susceptible parasites [48]. More spe-
cifically, avermectins' mode of action is to bind with high af-
finity to the parasite's glutamate-gated chloride channels,
increasing the chloride ion influx due to the changed
permeability of the cell membrane and hyperpolarization of
the parasite nerves [49]. The drug eventually interferes with
the transmission of nerve signals by its effect on neuro-
transmitter y-amino-butyric acid (GABA), which is important
in nematodes [45]. As a result, it could play a critical role
leading to the paralysis and death of parasites treated with
avermectins [Fig. 1B].Conclusion
Parasitic infections usually cause a broad of spectrum of clin-
ical outcomes depending on the species or stage of invading
parasites. Malaria is an ancient and deadly human infectious
disease. The discovery of artemisinin opened a new era in the
battle against chloroquine-resistant malaria. Following the
use of artemisinin-based combination therapies (ACTs) rec-
ommended by WHO [50], this newly discovered medicine hassignificantly reducedmalarial disease and deaths, particularly
the severe form caused by P. falciparum [51]. The parallel dis-
covery of avermectins has been of immeasurable value in the
control of onchocerciasis and lymphatic filariae. It is particu-
larly useful in killing the adult stages of these two devastating
diseases in association with infections by filariae. Generally,
filarial infections do not directly causemortality inmost cases.
However, they affect thehealth of individuals and families and
their socioeconomic condition. The 2015 Nobel Prize in Phys-
iology or Medicine honors the discoveries of antiparasitics by
Youyou Tu,WilliamC. Campbell, and Satoshi ~Omura, not only
in science but also in humanity.r e f e r e n c e s
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